Sun Pharma Advanced Research Company Ltd: Valuation Shifts Signal Changing Price Attractiveness

Valuation Metrics: A Closer Look

SPARC currently trades at a P/E ratio of 4.72, a significant departure from its previous valuation levels that were considered very expensive. This figure is markedly lower than many of its peers, such as Ajanta Pharma and Gland Pharma, which sport P/E ratios of 41.14 and 38.76 respectively. The company's price-to-book value stands at 5.52, which, while still elevated, is more moderate compared to the sector's very expensive players like Wockhardt and Rubicon Research, whose P/BV ratios exceed 40 in some cases.

Enterprise value multiples also reflect this valuation shift. SPARC's EV to EBITDA ratio is 4.97, and EV to EBIT is 5.00, both indicating a more reasonable pricing relative to earnings before interest, taxes, depreciation, and amortisation. These multiples are considerably lower than those of its very expensive peers, where EV to EBITDA can exceed 50, underscoring SPARC's improved relative valuation position.

Comparative Sector Analysis

Within the Pharmaceuticals & Biotechnology sector, SPARC's valuation now aligns more closely with the 'expensive' category rather than 'very expensive.' This repositioning is significant given the sector's typical valuation range. For instance, companies like J B Chemicals and Emcure Pharma maintain P/E ratios above 37, with EV to EBITDA multiples well above 19, highlighting SPARC's comparatively attractive pricing.

Moreover, SPARC's PEG ratio, a measure of valuation relative to earnings growth, is exceptionally low at 0.01, suggesting that the stock is undervalued relative to its growth prospects. This contrasts sharply with peers such as Ajanta Pharma (PEG 2.8) and Gland Pharma (PEG 0.78), indicating that SPARC may offer better value for investors seeking growth at a reasonable price.

Financial Performance and Quality Metrics

SPARC's robust financial health is underscored by its latest return on capital employed (ROCE) of 83.74% and return on equity (ROE) of 116.94%. These exceptional figures highlight the company's efficient capital utilisation and strong profitability, which support its valuation despite the recent downward adjustment in price multiples.

However, the stock has seen a day change of -3.25%, reflecting some short-term market pressure. Despite this, the year-to-date (YTD) return of 69.28% significantly outperforms the Sensex, which is down 8.81% over the same period. This divergence emphasises SPARC's strong relative performance amid broader market challenges.

Historical Returns and Market Context

Examining longer-term returns, SPARC's 1-year return stands at 41.15%, again outperforming the Sensex's negative 4.95%. However, over a 3-year horizon, the stock has marginally outperformed the benchmark with a 0.22% return versus Sensex's 15.00%, and over 5 and 10 years, it has underperformed with returns of -6.51% and -37.52% respectively, compared to Sensex's 48.87% and 178.37%. These figures suggest that while SPARC has delivered strong recent gains, its longer-term performance has been mixed, warranting careful consideration by investors.

Price Range and Trading Activity

SPARC's current price is ₹227.60, down from the previous close of ₹235.25. The stock has traded within a 52-week range of ₹108.20 to ₹289.00, indicating significant volatility. Today's trading range between ₹226.55 and ₹238.60 reflects active market interest and potential price discovery as investors reassess valuation in light of recent changes.

Valuation Grade Change and Market Implications

On 22 May 2026, SPARC's Mojo Grade was downgraded from Strong Buy to Buy, reflecting the shift in valuation from very expensive to expensive. The current Mojo Score of 77.0 still indicates a favourable outlook, supported by strong fundamentals and attractive valuation metrics relative to peers. This adjustment suggests a more cautious but positive stance, encouraging investors to weigh the improved price attractiveness against sector dynamics and company-specific risks.

Peer Comparison Highlights

Among its peers, SPARC stands out for its relatively low valuation multiples combined with high profitability metrics. While companies like Wockhardt and Rubicon Research remain very expensive with P/E ratios exceeding 100 and EV to EBITDA multiples above 50, SPARC's more moderate multiples offer a compelling alternative for value-conscious investors within the Pharmaceuticals & Biotechnology sector.

Outlook and Investor Considerations

Investors analysing SPARC should consider the company's strong return metrics and recent valuation moderation as signals of improved price attractiveness. The low PEG ratio suggests potential undervaluation relative to growth, while the downgrade in Mojo Grade advises a tempered approach. Given the stock's recent outperformance against the Sensex and its small-cap status, it may appeal to investors seeking growth opportunities with a margin of safety in valuation.

Conclusion

Sun Pharma Advanced Research Company Ltd's recent valuation adjustment from very expensive to expensive reflects a meaningful shift in price attractiveness. With a P/E ratio of 4.72 and a P/BV of 5.52, the stock now offers a more accessible entry point compared to its historically elevated multiples and many of its sector peers. Supported by exceptional ROCE and ROE figures, alongside a compelling PEG ratio, SPARC presents a balanced investment proposition for those seeking growth within the Pharmaceuticals & Biotechnology sector.

While the downgrade in Mojo Grade to Buy signals a need for cautious optimism, the company's strong recent returns and relative valuation appeal suggest it remains a noteworthy candidate for investors prioritising quality and value. As always, market participants should consider broader sector trends and individual risk tolerance when evaluating SPARC's prospects.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →